Optimal protocol for PTEN immunostaining; Role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues

Human Pathology

Volumn 45, Issue 3, 2014, Pages 522-532

  Maiques, Oscar ^a   Santacana, Maria ^a   Valls, Joan ^a   Pallares, Judit ^a   Mirantes, Cristina ^a   Gatius, Sónia ^a   García Dios, Diego Andrés ^b   Amant, Frederic ^b   Pedersen, Hans Christian ^c   Dolcet, Xavier ^a   Matias Guiu, Xavier ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Research and Development   (Denmark)

Author keywords

Immunohistochemistry; Preanalytical variables; Protocol; PTEN

Indexed keywords

IMMUNOHISTOCHEMISTRY; PREANALYTICAL VARIABLES; PROTOCOL; PTEN;

BREAST; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894062356     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.10.018     Document Type: Article

References (35)

1. P.A. Steck, M.A. Pershouse, and S.A. Jasser et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat Genet 15 1997 356 362
2. E.C. Chu, and A.S. Tarnawski PTEN regulatory functions in tumor suppression and cell biology Med Sci Monit 10 2004 235 241
3. J.O. Lee, H. Yang, and M.M. Georgescu et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association Cell 3 1999 323 334
4. M.S. Song, L. Salmena, and P.P. Pandolfi The functions and regulation of the PTEN tumour suppressor Nat Rev Mol Cell Biol 13 2012 283 296
5. N. Terakawa, Y. Kanamori, and S. Yoshida Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer Endocr Relat Cancer 10 2003 203 208
6. A. Velasco, E. Bussaglia, and J. Pallares et al. PIK3CA gene mutation in endometrial carcinoma: correlation with PTEN and K-RAS alterations Hum Pathol 37 2006 1465 1472
7. S.T. Pradeep, M. Gayatry, and C. Sarah et al. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer Carcinogenesis 2013 [in press]
8. A.M. Mendes-Pereira, S.A. Martin, and R. Brough et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 2009 315 322
9. Y. Nagata, K.H. Lan, and X. Zhou et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
10. K. Berns, H.M. Horlings, and B.T. Hennessy et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistant in breast cancer Cancer Cell 12 2007 297 299
11. K. Liang, F.J. Esteva, and C. Albarracin et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation Cancer Cell 18 2010 423 435
12. J. Pallares, E. Bussaglia, and J.L. Martinez-Guitarte et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities Mod Pathol 18 2005 719 727
13. B. Djordjevic, B.T. Hennessy, and J. Li et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing Mod Pathol 25 2012 699 708
14. N. Kapucuoglu, F. Aktepe, H. Kaya, S. Bircan, N. Karahan, and M. Ciris Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index Pathol Res Pract 203 2007 153 162
15. T.L. Lotan, B. Gurel, and S. Sutcliffe et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
16. A. Perren, L.P. Weng, and A.H. Boag et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast Am J Pathol 155 1999 1253 1260
17. J.D. Croxtall, M.G. Elder, and J.O. White Hormonal control of proliferation in the Ishikawa endometrial adenocarcinoma cell line J Steroid Biochem 35 1990 665 669
18. D.L. Way, D.S. Grosso, J.R. David, E.A. Surwit, and C.D. Christian Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture In Vitro 19 1983 147 158
19. K. Podsypanina, L.H. Ellenson, and A. Nemes et al. Mutation of PTEN/MMAC1 in mice causes neoplasias in multiple organ systems Proc Natl Acad Sci U S A 98 1999 10320 10325
20. C. Mirantes, N. Eritja, and M.A. Dosil et al. An inducible Knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias Dis Model Mech 6 2013 710 720
21. K.B. Engel, and H.M. Moore Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue Arch Pathol Lab Med 135 2011 537 543
22. S. Agrawal, and C. Eng Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer Hum Mol Genet 15 2006 777 787
23. X. Hu, P.P. Pandolfi, Y. Li, J.A. Koutcher, M. Rosenblum, and E.C. Holland mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma Neoplasia 7 2005 356 368
24. T. Sano, H. Lin, and X. Chen et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis Cancer Res 59 1999 1820 1824
25. M.E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W.R. Sellers Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Res 59 1999 4291 4296
26. X. Dolcet, D. Llobet, J. Pallares, M. Rue, J.X. Comella, and X. Matias-Guiu FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis Lab Invest 85 2005 885 894
27. H. Tashiro, M.S. Blazes, and R. Wu et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies Cancer Res 57 1997 3935 3940
28. Llobet D., Pallares J., Yeramian A., Santacana M., Eritja N., Velasco A., Dolcet X., and Matias-Guiu X. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical view points J Clin Pathol 62 2009 777 785
29. L. George, Mutter, and L. Ming-Chieh L et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 2000 924 931
30. R.L. Levine, C.B. Cargile, M.S. Blazes, B. van Rees, R.J. Kurman, and L.H. Ellenson PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma Cancer Res 58 1998 3254 3258
31. Y. Kanamori, J. Kigawa, and H. Itamochi et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy Int J Cancer 100 2002 686 689
32. O. Gimm, A. Perren, and L.P. Weng et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors Am J Pathol 156 2000 1693 1700
33. A. Alimonti, A. Carracedo, and J.G. Clohessy et al. Subtle variations in PTEN dose determine cancer susceptibility Nat Genet 42 2010 454 458
34. A.H. Berger, A.G. Knudson, and P.P. Pandolfi A continuum model for tumour suppression Nature 476 2011 163 169
35. T. Fujita, H. Doihara, and K. Kawasaki et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer Br J Cancer 94 2006 247 252